 | Up a level |
2021
Fischer, Matthias, Moreno, Lucas, Ziegler, David S., Marshall, Lynley, V, Zwaan, C. Michel, Irwin, Meredith S., Casanova, Michela, Sabado, Constantino, Wulff, Beate, Stegert, Mario, Wang, Luojun, Hurtado, Felipe K., Branle, Fabrice, Geoerger, Birgit and Schulte, Johannes H. (2021). Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. Lancet Oncol., 22 (12). S. 1764 - 1777. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488
2020
Schulte, Johannes H., Moreno, Lucas, Ziegler, David Simon, Marshall, Lynley V., Zwaan, C. Michel, Irwin, Meredith, Casanova, Michela, Sabado, Constantino, Wulff, Beate, Stegert, Mario, Wang, Luojun, Hurtado, Felipe K., Branle, Fabrice, Fischer, Matthias and Geoerger, Birgit (2020). Final analysis of phase I study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK). J. Clin. Oncol., 38 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
2017
De Castro, Gilberto, Jr., Tan, Daniel Shao-Weng, Crino, Lucio, Wu, Yi Long, Paz-Ares, Luis, Wolf, Juergen, Geater, Sarayut, Orlov, Sergey, Cortinovis, Diego, Yu, Chong-Jen, Hochmair, Maximilian, Cortot, Alexis, Tsai, Chun-Ming, Moro-Sibilot, Denis, Campelo, Rosario Garcia, Branle, Fabrice, Sen, Paramita, Mcculloch, Tracey and Soria, Jean-Charles (2017). First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK plus ) NSCLC: A Randomized, Phase 3 Study (ASCEND-4). J. Thorac. Oncol., 12 (1). S. S7 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
Soria, Jean-Charles, Tan, Daniel S. W., Chiari, Rita, Wu, Yi-Long 
ORCID: 0000-0002-3611-0258, Paz-Ares, Luis, Wolf, Juergen, Geater, Sarayut L., Orlov, Sergey ORCID: 0000-0001-6080-8042, Cortinovis, Diego, Yu, Chong-Jen ORCID: 0000-0001-5664-9392, Hochmair, Maximillian, Cortot, Alexis B., Tsai, Chun-Ming, Moro-Sibilot, Denis, Campelo, Rosario G., McCulloch, Tracey, Sen, Paramita, Dugan, Margaret, Pantano, Serafino, Branle, Fabrice, Massacesi, Cristian and de Castro, Gilberto, Jr.
(2017).
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Lancet, 389 (10072).
S. 917 - 930.
NEW YORK:
ELSEVIER SCIENCE INC.
ISSN 1474-547X
Tan, Daniel Shao-Weng, Soria, Jean-Charles, De Castro, Gilberto, Jr., Wu, Yi Long, Paz-Ares, Luis, Wolf, Juergen, Geater, Sarayut, Orlov, Sergey, Cortinovis, Diego, Yu, Chong-Jen, Hochmair, Maximilian, Cortot, Alexis, Tsai, Chun-Ming, Moro-Sibilot, Denis, Campelo, Rosario Garcia, Branle, Fabrice, Sen, Paramita, Struebbe, Gero, Mcculloch, Tracey and Crino, Lucio (2017). PROs With Ceritinib Versus Chemotherapy in Patients With Previously Untreated ALK-rearranged Nonsquamous NSCLC (ASCEND-4). J. Thorac. Oncol., 12 (1). S. S1176 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380